Pfizer Inc., New York, New York, was awarded a $442,132,500 modification (P00001) to contract W58P05-22-C-0001 to produce 835,000 PAXLOVID oral antiviral therapeutic treatments for administration, vendor-managed inventory and distribution activities. Work will be performed in New York, New York, with an estimated completion date of March 31, 2023. Fiscal 2022 research, development, test and evaluation, Army funds in the amount of $442,132,500 were obligated at the time of the award. U.S. Army Contracting Command, Aberdeen Proving Ground, Maryland, is the contracting activity. (Awarded Jan. 7, 2022)